Items Tagged ‘IMAB362’

June 28th, 2016

Novel Antibody Improves Survival in Advanced Stomach Cancer

By

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, […]

View full entry

Tags: 2016, advanced, asco, Gastric Cancer, GEJ cancer, IMAB362, News, Stages III-IV Gastric Cancer, stomach cancer


June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission